Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 223 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin + Insulin Clear all
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

NCT03029702
View directory record Official record
Conditions
Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions
Insulin, Glyburide, Metformin
Drug
Lead sponsor
Maisa N. Feghali, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 2, 2026, 1:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

NCT00851903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 71 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

NCT01388361
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin aspart, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
48
States / cities
Concord, California • La Jolla, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

NCT00108615
View directory record Official record
Conditions
Glucose Metabolism Disorders, Diabetes
Interventions
Metformin, Pioglitazone, CT scans, Oral glucose tolerance test
Drug · Radiation · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2008 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 2, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

NCT01482286
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

NCT02152371
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo, Insulin Glargine, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fresno, California • San Mateo, California • Tustin, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

NCT02429258
View directory record Official record
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717
View directory record Official record
Conditions
Diabetes
Interventions
metformin\pioglitazone\exenatide, metformin, glyburide and glargine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin and Muscle in Insulin-resistant Older Veterans

NCT01804049
View directory record Official record
Conditions
Prediabetes
Interventions
metformin, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

NCT01718093
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin, Metformin, Sitagliptin + Metformin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

NCT01813929
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 2, 2026, 1:52 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Metformin on Muscle Health of Older Adults

NCT03107884
View directory record Official record
Conditions
Muscle Atrophy, Insulin Resistance
Interventions
Metformin (Bed Rest), Placebo (Bed Rest), Metformin (2 week run-in only), Placebo (2 week run-in only)
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01889667
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 2, 2026, 1:52 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Metformin to Treat Obesity in Children With Insulin Resistance

NCT00005669
View directory record Official record
Conditions
Hyperinsulinemia, Obesity
Interventions
Metformin HCL, Placebo
Drug
Lead sponsor
Jack Yanovski, M.D.
NIH
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Insulin Glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

NCT00789191
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, sitagliptin, metformin, sulphonylurea
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 2, 2026, 1:52 AM EDT